This Article Full Text Full Text (PDF) Erratum (v24,p3221) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaufmann, M. Articles by von Minckwitz, G. Search for Related Content PubMed PubMed Citation Articles by Kaufmann, M. Articles by von Minckwitz, G.

Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

Manfred Kaufmann, Gabriel N. Hortobagyi, Aron Goldhirsch, Suzy Scholl, Andreas Makris, Pinuccia Valagussa, Jens-Uwe Blohmer, Wolfgang Eiermann, Raimund Jackesz, Walter Jonat, Annette Lebeau, Sibylle Loibl, William Miller, Sigfried Seeber, Vladimir Semiglazov, Roy Smith, Rainer Souchon, Vered Stearns, Michael Untch, Gunter von Minckwitz

From the J.W. Goethe-University, Frankfurt am Main; St. Gertrauden, Berlin; Krankenhuas vom Roten Kreuz, Frauenklinik; Ludwig-Maximillians University, Institute of Pathology; Ludwig-Maximillian University, München; University Hospital, Kiel; Tumorzentrum, Essen; Allgemeines Krankenhaus Hagen, Hagen; German Breast Group, Neu-Isenburg/Frankfurt am Main, Germany; European School of Oncology; Istituto Nazionale Tumori; Milano, Italy; Institute Curie, Paris, France; Mount Vernon Hospital, Northwood, Middlesex; Western General Hospital; University of Edinburgh, Edinburgh, United Kingdom; Universtitätsklinik für Chirurgie, Wien, Austria; NN Petrov Research Inst of Oncology, St Petersburg, Russia; The University of Texas M.D. Anderson Cancer Center, Houston, TX; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Address reprint requests to address: Manfred Kaufmann, MD, Professor and Head of the Department of Obstetrics and Gynecology, J.W. Goethe-University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; e-mail: M.Kaufmann{at}em.uni-frankfurt.de

Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				J. Emmering, N. C. Krak, J. J. M. Van der Hoeven, M. D. Spreeuwenberg, J. W. R. Twisk, S. Meijer, H. M. Pinedo, and O. S. Hoekstra Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology Ann. Onc., September 1, 2008; 19(9): 1573 - 1577. [Abstract] [Full Text] [PDF]

				G. von Minckwitz, S. Kummel, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S. D. Costa, C. Jackisch, et al. Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial J Natl Cancer Inst, April 16, 2008; 100(8): 542 - 551. [Abstract] [Full Text] [PDF]

				G. von Minckwitz, S. Kummel, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S. D. Costa, C. Jackisch, et al. Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study J Natl Cancer Inst, April 16, 2008; 100(8): 552 - 562. [Abstract] [Full Text] [PDF]

				S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff Locally Advanced and Inflammatory Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 786 - 790. [Full Text] [PDF]

				M. Fatouros, G. Baltoyiannis, and D. H. Roukos The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations Ann. Surg. Oncol., January 1, 2008; 15(1): 21 - 33. [Abstract] [Full Text] [PDF]

				S. Dawood, K. Broglio, S.-W. Kau, R. Islam, W. F. Symmans, T. A. Buchholz, S. E. McGuire, F. Meric-Bernstam, M. Cristofanilli, G. N. Hortobagyi, et al. Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response Oncologist, January 1, 2008; 13(1): 6 - 15. [Abstract] [Full Text] [PDF]

				W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer, V. Valero, L. Assad, A. Poniecka, B. Hennessy, M. Green, et al. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy J. Clin. Oncol., October 1, 2007; 25(28): 4414 - 4422. [Abstract] [Full Text] [PDF]

				F. Peintinger, K. Anderson, C. Mazouni, H. M. Kuerer, C. Hatzis, F. Lin, G. N. Hortobagyi, W. F. Symmans, and L. Pusztai Thirty-Gene Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4078 - 4082. [Abstract] [Full Text] [PDF]

				R. M. Layman, D. G. Thomas, K. A. Griffith, J. B. Smerage, M. A. Helvie, M. A. Roubidoux, K. M. Diehl, L. A. Newman, M. S. Sabel, J. A. Hayman, et al. Neoadjuvant Docetaxel and Capecitabine and the Use of Thymidine Phosphorylase as a Predictive Biomarker in Breast Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4092 - 4097. [Abstract] [Full Text] [PDF]

				C. Mazouni, F. Peintinger, S. Wan-Kau, F. Andre, A. M. Gonzalez-Angulo, W. F. Symmans, F. Meric-Bernstam, V. Valero, G. N. Hortobagyi, and L. Pusztai Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome J. Clin. Oncol., July 1, 2007; 25(19): 2650 - 2655. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann. Onc., July 1, 2007; 18(7): 1133 - 1144. [Abstract] [Full Text] [PDF]

				B. P. Coudert, R. Largillier, L. Arnould, P. Chollet, M. Campone, D. Coeffic, F. Priou, J. Gligorov, X. Martin, V. Trillet-Lenoir, et al. Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial J. Clin. Oncol., July 1, 2007; 25(19): 2678 - 2684. [Abstract] [Full Text] [PDF]

				C Natoli, E Cianchetti, N Tinari, D Angelucci, A Grassadonia, M Zilli, C Ficorella, E Ricevuto, S Grossi, M De Tursi, et al. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer Ann. Onc., June 1, 2007; 18(6): 1015 - 1020. [Abstract] [Full Text] [PDF]

				S. Loibl, G. von Minckwitz, G. Raab, J.-U. Blohmer, S. D. Costa, B. Gerber, H. Eidtmann, S. Petrich, J. Hilfrich, C. Jackisch, et al. Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial Ann. Surg. Oncol., November 1, 2006; 13(11): 1434 - 1442. [Abstract] [Full Text] [PDF]

				L. Leichman Neoadjuvant Chemotherapy for Disseminated Colorectal Cancer: Changing the Paradigm J. Clin. Oncol., August 20, 2006; 24(24): 3817 - 3818. [Full Text] [PDF]